ReviewGene therapy2008
How not to be seen: immune-evasion strategies in gene therapy.
Review in Gene therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- CRISPR-Cas9-mediated knock-in of cytomegalovirus US2 provides an alternative strategy for generating hypoimmunogenic hiPSC lines.Scientific reports · 2026Article
- From bench to bedside: the future of stable lentiviral packaging cell lines in gene therapy.Gene therapy · 2025Article
- Cryo-electron Microscopy of Adeno-associated Virus.Chemical reviews · 2022Review
- Overview and Update on Methods for Cargo Loading into Extracellular Vesicles.Processes (Basel, Switzerland) · 2021Article
- Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy.Nature biomedical engineering · 2019Article
- Gene therapy and peripheral nerve repair: a perspective.Frontiers in molecular neuroscience · 2015Article
- Developing a potentially immunologically inert tetracycline-regulatable viral vector for gene therapy in the peripheral nerve.Gene therapy · 2014Article
- An adaptable system for improving transposon-based gene expression in vivo via transient transgene repression.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2013Article
- Genetically engineered human islets protected from CD8-mediated autoimmune destruction in vivo.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Capsid antibodies to different adeno-associated virus serotypes bind common regions.Journal of virology · 2013Article
- Reprogrammed quiescent B cells provide an effective cellular therapy against chronic experimental autoimmune encephalomyelitis.European journal of immunology · 2011Article
- Transgene expression levels determine the immunogenicity of transduced hematopoietic grafts in partially myeloablated mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- Emerging strategies for cell and gene therapy of the muscular dystrophies.Expert reviews in molecular medicine · 2009Review
- Medical bioremediation of age-related diseases.Microbial cell factories · 2009Article
- Influence of method of systemic administration of adenovirus on virus-mediated toxicity: focus on mortality, virus distribution, and drug metabolism.Journal of pharmacological and toxicological methodsArticle
- Engineered miniature H1 promoters with dedicated RNA polymerase II or III activity.The Journal of biological chemistryArticle
- Correction of glycogenosis type 2 by muscle-specific lentiviral vector.In vitro cellular & developmental biology. AnimalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of efficient and safe vectors for gene delivery paved the way for evolution of gene therapy as a new modality for treatment of various inherited disorders and for cancer. The current vectors, viral and non-viral, have their limitations. Innate and adaptive immune responses to vector particles and components may restrict the efficiency of gene transfer and the persistence of expression of the transgene. Results from preclinical studies in animals and more recently data from clinical studies have demonstrated the potential impact of the cellular and the humoral immune response on the therapeutic efficacy. Not only the vector components, but also the transgene products may induce an immune response that negatively affects the therapeutic efficacy. The induction of a cytotoxic T-cell response to transgene-encoded peptides, as well as the production of antibodies directed against secreted proteins have been reported in preclinical and clinical studies, and these may thwart those applications that require long-term expression. Here we will review some of the options to blunt the acquired immune responses to transgene-encoded polypeptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.